Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the efficacy of three dose regimens of ACZ885 ( (1) 600 mg i.v. loading dose plus 300 mg s.c. q2wk, (2) 300 mg s.c. q2wk, (3) 150 mg s.c. q4wk) compared to placebo as add-on treatment in patients with active RA despite stable treatment of MTX at the maximum tolerated dose (<_ 25 mg/week) for at least 12 weeks, by assessing the response to treatment (ACR50 criteria) after 12 weeks.
Critère d'inclusion
- active rheumatoid arthritis